Delivery Order SPE2DB20D7059-SPE2DB25FGSW3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a contract ceiling value of $29,588.62. This firm fixed-price delivery order, which is expected to conclude by August 15, 2025, represents a competitively awarded, non-set-aside contract with performance directed to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award demonstrates the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $5,976.54 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $10,940.38. This firm fixed-price delivery order, which is not set-aside and represents the culmination of competitive procurement, is scheduled for completion by August 7, 2025. The award supports the federal medical supply chain, with performance occurring at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $23,024.39. This firm fixed-price delivery order represents a non-set-aside award issued under competitive procurement and is scheduled for ultimate completion by August 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform all work at...
- The Defense Logistics Agency awarded a delivery order valued at $16,991.63 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of September 15, 2025. The delivery order was issued on September 12, 2025, with performance to take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order valued at $35,436.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a single line item fulfilling pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Otezla 30 mg tablets (60-count) with a ceiling value of $9,280.24. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania, with an ultimate completion date of September 10, 2025. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,707.42 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single transaction within AmerisourceBergen's...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for supply of Otezla 30 mg tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $48,488.62 with an ultimate completion date of July 30, 2025, represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $36,477.84 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Otezla 30 mg tablets (60-count units). The contract is a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB20D7059Indefinite Delivery Contract
- SPE2DB20D7059-SPE2DB25FGSW3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,623.24 to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Otezla 30 mg tablets (60-count). The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 24, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen leverages this comprehensive IDC vehicle to supply a broad range of pharmaceutical products and medical supplies supporting military healthcare programs worldwide. The company's federal contracting portfolio demonstrates consistent success in meeting DLA medical supply requirements across multiple therapeutic domains, positioning it as a key provider for defense healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 9/23/25 |